Regeneron elects Craig B. Thompson, M.D. as director; board expands to 13 members

REGENERON PHARMACEUTICALS, INC.

Dr. Craig B. Thompson elected as director effective October 3, 2022; board expands from 12 to 13.
Appointed to Technology Committee; term runs until 2023 Annual Shareholder Meeting.
Compensation follows standard non-employee director practices described in April 21, 2022 proxy.
No arrangement or understanding with any other person regarding his selection as director.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig B. Thompson

Director

REGN · REGENERON PHARMACEUTICALS, INC.

Effective: 2022-10-03
Filed: October 3, 2022, 7:59 PM ET

On October 3, 2022, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Craig B. Thompson, M.D. as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Craig B. Thompson was elected as Director at REGENERON PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

On October 3, 2022, the board of directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (the “ Company ”) elected Craig B. Thompson, M.D. as a director.

View on SEC.gov

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-104901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.